首页膀胱肿瘤治疗及预后证据详情

经尿道膀胱肿瘤切除术后应用吡柔比星及丝裂霉素 C 进行升温灌注化疗效果的荟萃分析

原文: 2019 年 发布于 International Journal of Clinical and Experimental Medicine 36 卷 第 1 期 979 浏览量:187次

作者: 马杰锋 管庆军 单中杰

作者单位: Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH. Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH. Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH Case Comprehensive Cancer Center, Case Western Reserve School of Medicine, Cleveland, OH. Department of Urology, Fox Chase Cancer Center, Philadelphia, PA. Department of Population and Quantitative Health Science, Case Western Reserve School of Medicine, Cleveland, OH. Department of Urology, University of Washington School of Medicine, Seattle, WA. Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH Case Comprehensive Cancer Center, Case Western Reserve School of Medicine, Cleveland, OH. Electronic address: laura.bukavina@fccc.edu.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.1089/end.2021.0688

关键词: biomarkers ‹› urine bladder cancer ‹› miRNA ‹› microRNA ‹›

文献简介

BACKGROUND: Previous quality of life (QoL) literature in bladder cancer (BC) patients has focused on finding the preferred urinary diversion while little is known about the QoL of patients in medical oncological treatment (MOT). We performed a systematic review to assess the existing literature on QoL in patients with muscle-invasive BC (MIBC) undergoing MOT. METHODS: A systematic search of Pubmed and Embase was performed. Inclusion criteria were studies containing QoL data for patients undergoing chemo- and/or radiotherapy. We extracted all QoL scorings at different time intervals and on the six most prevalent domains: overall QoL, urinary, bowel sexual symptoms, pain and fatigue. The study was carried out according to PRISMA guidelines for systematic reviews and GRADE was used to rate the quality of evidence from the included studies. RESULTS: Of 208 papers reviewed, 21 papers were included. Twenty-one different QoL instruments were applied. The only data on QoL during chemotherapy was from patients in clinical trials investigating new treatments. No studies were found for patients in neoadjuvant treatment. The level of evidence at each time point was graded as very low to moderate. From the studies included the overall QoL seemed inversely related to the organ-specific impairment from sexual and urinary symptoms and increased with decreasing organ-specific symptoms for long term survivors > 6 months after treatment. CONCLUSIONS: Collection of data on QoL from patients with MIBC disease undergoing MOT has been sparse and diverse. The present data can act as a summary but prompts for more prospective collection of QoL data from BC patients.

热门文献